RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Crimea Power Outage After Ukrainian Drone Attack, Russian Authorities Say 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Trump Administration Rejects Claims of Rift Between JD Vance and Marco Rubio on Iran Policy 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Iran Attack in Strait of Hormuz Pushes Oil Prices Higher 
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
